Identifying alternatively spliced targets to develop T cell receptor (TCR) T cell therapies for myelodysplastic neoplasms (MDS)
2024
Overview
Fred Hutchinson Cancer Center was awarded a $250,000 grant over two years to support early career researcher Dr. Melinda A. Biernacki.
Details
Dr. Biernacki will conduct this research with the support of her mentor Dr. Aude Chapuis to examine alternatively spliced neoepitopes from a recurrent SRSF2 mutation and begin preclinical development of TCR-engineered T cells (TCR-T) directed against them.
Learn more about Fred Hutchinson Cancer Center.